Fresenius Medical Care AG (FMS)
18.77
+0.38
(+2.07%)
USD |
NYSE |
Apr 15, 16:00
18.74
-0.02
(-0.13%)
Pre-Market: 20:00
Fresenius Medical Care Revenue (Quarterly): 5.371B for Dec. 31, 2023
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 5.371B |
| September 30, 2023 | 5.375B |
| June 30, 2023 | 5.262B |
| March 31, 2023 | 5.053B |
| December 31, 2022 | 5.109B |
| September 30, 2022 | 5.134B |
| June 30, 2022 | 5.067B |
| March 31, 2022 | 5.104B |
| December 31, 2021 | 5.315B |
| September 30, 2021 | 5.237B |
| June 30, 2021 | 5.207B |
| March 31, 2021 | 5.073B |
| December 31, 2020 | 5.246B |
| September 30, 2020 | 5.161B |
| June 30, 2020 | 5.019B |
| March 31, 2020 | 4.952B |
| December 31, 2019 | 5.072B |
| September 30, 2019 | 4.914B |
| June 30, 2019 | 4.881B |
| March 31, 2019 | 4.694B |
| December 31, 2018 | 4.906B |
| September 30, 2018 | 4.718B |
| June 30, 2018 | 5.031B |
| March 31, 2018 | 4.884B |
| December 31, 2017 | 5.215B |
| Date | Value |
|---|---|
| September 30, 2017 | 5.097B |
| June 30, 2017 | 4.919B |
| March 31, 2017 | 4.845B |
| December 31, 2016 | 4.765B |
| September 30, 2016 | 4.701B |
| June 30, 2016 | 4.548B |
| March 31, 2016 | 4.320B |
| December 31, 2015 | 4.862B |
| September 30, 2015 | 4.179B |
| June 30, 2015 | 4.137B |
| March 31, 2015 | 4.126B |
| December 31, 2014 | 4.930B |
| September 30, 2014 | 4.295B |
| June 30, 2014 | 3.855B |
| March 31, 2014 | 3.550B |
| December 31, 2013 | 3.565B |
| September 30, 2013 | 3.601B |
| June 30, 2013 | 3.627B |
| March 31, 2013 | 3.571B |
| December 31, 2012 | 3.338B |
| September 30, 2012 | 3.328B |
| June 30, 2012 | 3.477B |
| March 31, 2012 | 3.193B |
| December 31, 2011 | 3.836B |
| September 30, 2011 | 3.313B |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
4.881B
Minimum
Jun 2019
5.375B
Maximum
Sep 2023
5.134B
Average
5.109B
Median
Dec 2022
Revenue (Quarterly) Benchmarks
| DaVita Inc | 3.146B |
| Biodexa Pharmaceuticals Plc | -- |
| NuCana PLC | -- |
| Biophytis SA | -- |
| TC BioPharm (Holdings) PLC | -- |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | 202.38M |
| Total Expenses (Quarterly) | 4.690B |
| EPS Diluted (Quarterly) | 0.3446 |
| Enterprise Value | 19.38B |
| Gross Profit Margin (Quarterly) | 27.06% |
| Profit Margin (Quarterly) | 3.77% |
| Earnings Yield | 4.90% |
| Operating Earnings Yield | 15.07% |
| Normalized Earnings Yield | 5.308 |